Roivant Sciences (ROIV) director sells 41,861 common shares

Rhea-AI Filing Summary

Roivant Sciences Ltd. director Melissa B. Epperly reported an open-market sale of 41,861 common shares on March 16, 2026 at a weighted average price of $28.68 per share. The shares were sold in multiple trades priced between $28.50 and $28.84. After this transaction, she directly holds 15,804 common shares of Roivant Sciences.

Insights

Equity ownership & insider-trading analyst

Roivant director executed a sizable open-market share sale.

Director Melissa B. Epperly executed an open-market sale of 41,861 common shares of Roivant Sciences Ltd. at a weighted average price of $28.68 per share on March 16, 2026. The sale was executed through multiple trades between $28.50 and $28.84.

This is a strong-signal transaction because it is an open-market sale coded "S" rather than a tax or grant-related movement. Following the sale, Epperly directly holds 15,804 shares, indicating that the transaction reduced her direct position significantly while leaving a smaller continuing stake.

No derivative positions are listed in the current data, suggesting the filing reflects only common-share activity. Future company filings may provide additional context on any subsequent insider transactions or changes to Epperly’s ownership levels.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Epperly Melissa B,

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/16/2026		S		41,861	D	$28.68(1)	15,804	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Remarks:

	By: /s/ Jo Chen, as Attorney-in-Fact for Melissa B. Epperly	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Roivant Sciences (ROIV) report for Melissa B. Epperly?

Roivant Sciences reported that director Melissa B. Epperly completed an open-market sale of 41,861 common shares on March 16, 2026. The filing classifies the transaction under code "S," indicating a standard sale in the market or a private transaction.

At what prices did Melissa B. Epperly sell Roivant Sciences (ROIV) shares?

The reported weighted average sale price was $28.68 per Roivant Sciences common share. According to the filing footnote, individual trades occurred in a range from $28.50 to $28.84, with the insider offering to provide full trade-by-trade detail upon request.

How many Roivant Sciences (ROIV) shares does Melissa B. Epperly hold after the sale?

After the reported transaction, Melissa B. Epperly directly holds 15,804 common shares of Roivant Sciences. This figure reflects her remaining position immediately following the 41,861-share open-market sale disclosed in the Form 4 insider trading report.

Was Melissa B. Epperly’s Roivant Sciences (ROIV) sale an open-market transaction?

Yes. The transaction is coded "S" and described as an open-market sale or private transaction of common shares. The filing notes that the sales occurred across multiple trades within a defined price range rather than as a single block trade.

Does the Roivant Sciences (ROIV) Form 4 show any derivative exercises by Melissa B. Epperly?

No derivative transactions are listed in this Form 4. The filing shows only a non-derivative transaction involving common shares, with no option exercises, conversions, or other derivative activities reported for Melissa B. Epperly in this particular report.

What does the weighted average price mean in the Roivant Sciences (ROIV) insider sale?

The weighted average price of $28.68 represents the average price across all individual trades in the sale. The filing explains that shares were sold in multiple transactions between $28.50 and $28.84, and detailed price-by-price information is available upon request.